Healthcare / BiotechnologyCopenhagen
$339.00
+11.00 (+3.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-27.1M · quality 55.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.5B
P/E
3.3x
↓EV/EBITDA
2.6x
↓ROE
147.5%
↑Gross Margin
97.0%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+136.5%
FCF CAGR
+449.9%
FCF margin
64.2%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.64B · net income $1.69B · FCF $1.69B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.64B | $2.64B | $265.7M | $205.0M | $199.4M |
| Net Income | $1.69B | $1.69B | $-36.5M | $-44.5M | $4.3M |
| EBITDA | $2.18B | $2.18B | $-20.1M | $-28.1M | $14.7M |
| EPS | — | — | -2.20 | -2.90 | 0.26 |
| Gross Margin | 97.0% | 97.0% | 61.9% | 56.1% | 49.0% |
| Operating Margin | 81.5% | 81.5% | -18.8% | -23.3% | -0.6% |
| Net Margin | 64.1% | 64.1% | -13.7% | -21.7% | 2.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.21 | 0.15 | 0.64 |
| Current Ratio | 13.63 | 13.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.69B | $1.69B | $-27.1M | $-60.6M | $10.2M |
| Returns | |||||
| ROE | 147.5% | 147.5% | -8.1% | -9.3% | 4.0% |
| Valuation | |||||
| P/E | 3.30 | 3.30 | — | — | — |
| EV/EBITDA | 2.58 | 2.58 | — | — | — |
| P/B | 4.83 | 4.83 | 22.07 | 3.90 | — |
| Growth & Yield | |||||
| Revenue Growth | 892.2% | 892.2% | 29.6% | 2.8% | — |
| EPS Growth | — | — | 24.1% | -1200.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.20 → n/d
Residual
-13.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.